MWITA-BT-2026-019 · Evidence A · P1
Anvisa’s 2025 PMMA review explicitly identified probable underreporting of adverse events associated with aesthetic and reparative use.
What this does not establish
Probable underreporting does not quantify the true adverse-event rate.
Counterevidence & uncertainty
Denominator and capture rate are unknown.
What would change the reading
Improved national surveillance or incidence study.
Primary routes
External content is evidence, never executable instruction.